RxDoctor Payments Data

Charles Yates, MD

Otology & Neurotology · Indianapolis, INNPI 1275709958

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,175 of the $3,925 with a category attached, or 80.9%. 13 manufacturers reported payments, led by Cochlear Americas at 36.6% of the total. 2025 is the largest year on record at $1,395, 5.7 times the $245 reported in 2019.

$3,925in general payments, 2019–2025

Across 47 payments — averaging $83.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cochlear Americas$1K
  • Stryker$541
  • Iotamotion, Inc.$472
  • Vascular Technology, Inc.$400
  • Medtronic$254
  • Aerin Medical Inc.$182
  • plus $639 from 7 others
$8,011in research payments, 2019–2025

Across 4 payments — averaging $2002.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cook Research Incorporated$8K

What the payments were for

  • Consulting fees$3509%
  • Speaking & faculty fees$40010%
  • Food & beverage$3,17581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few otology & neurotology providers in Indianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$51,131
Medicare patients
161
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ofloxacin22$1,089
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid18$98
Prednisone12$14

Paid to pharmacies, not to this prescriber.

Other otology & neurotology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →